Shiseido begins trading on OTCQX
NEW YORK — Shiseido Co. — a Japanese cosmetics manufacturer whose brands include Global Shiseido, bareMinerals and Nars — has chosen to have its American Depositary Receipts trade on OTCQX, the OTC Markets Group has announced.
Shiseido begins trading on April 1 on OTCQX International Premier, a segment of the OTCQX marketplace reserved for non-U.S. companies that are listed on a qualified international exchange and provide their home country disclosure to U.S. investors.
"We are pleased to welcome Shiseido, one of the world’s largest cosmetics and beauty companies and a respected Japanese brand, to the OTCQX marketplace," stated R. Cromwell Coulson, president and CEO of OTC Markets Group. "By joining OTCQX, Shiseido ensures its U.S. investors will have transparent trading and convenient access to its news and financial disclosure, making it easier for them to analyze, value and trade its securities. We look forward to working with Shiseido’s management team as they continue to grow their presence in the U.S. market."
Ralph Lauren Fragrances introduces Midnight Romance
NEW YORK —- Ralph Lauren Fragrances is expanding its portfolio with the new Midnight Romance for women.
Available in select retailers beginning April, Midnight Romance is designed to capture Ralph Lauren’s understanding of feminine sensitivity and beauty. Each bottle design detail exhibits the sensual mystique of the fragrance. The transparent bottle with its soft pink juice is sealed with a shiny metallic black cap with silver outline.
The top notes are raspberry, Italian bergamont and juicy lychee. The mid notes are peony, jasmine sambac and freesia. The base notes are black vanilla, iris absolute and ambrox.
To bring the Midnight Romance love story to life and portray the cinematic start to many romances, director Bruce Weber created a short film in black and white to capture the essence of midnight passion. This story also welcomes a new Ralph Lauren Fragrances face, Anna Selezneva, a current star on the Ralph Lauren fashion runway.
Teva announces availability of bioequivalent to osteoporosis treatment Evista
JERUSALEM — Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP. This product is AB rated and bioequivalent to Evista tablets.
Raloxifene hydrochloride tablets, USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Evista 60 mg Tablets marketed by Eli Lilly and Co., had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013.